Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that CD30 + status confers therapeutic sensitivity to Brentuximab vedotin in patients with Hodgkin Lymphoma.
This statement is based on a regulatory approval from the Health Service Executive:
Treatment of adult patients with CD30+ Hodgkins Lymphoma (HL) at increased risk of relapse or progression following an autologous haematopoietic stem cell transplant (ASCT).